Literature DB >> 22846731

Genetic testing by cancer site: breast.

Kristen Mahoney Shannon1, Anu Chittenden.   

Abstract

Women in the United States have a 12% lifetime risk of developing breast cancer. Although only about 5% to 10% of all cases of breast cancer are attributable to a highly penetrant cancer predisposition gene, individuals who carry a mutation in one of these genes have a significantly higher risk of developing breast cancer, as well as other cancers, over their lifetime compared with the general population. The ability to distinguish those individuals at high risk allows health care providers to intervene with appropriate counseling and education, surveillance, and prevention-with the overall goal of improved survival for these individuals. This article focuses on the identification of patients at high risk for breast cancer and provides an overview of the clinical features, cancer risks, causative genes, and medical management for the most clearly described hereditary breast cancer syndromes. Newer genes that have also been implicated in familial breast cancer are also briefly reviewed.

Entities:  

Mesh:

Year:  2012        PMID: 22846731     DOI: 10.1097/PPO.0b013e318260946f

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  8 in total

1.  Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease.

Authors:  Edward D Esplin; Ling Oei; Michael P Snyder
Journal:  Pharmacogenomics       Date:  2014-11       Impact factor: 2.533

2.  Health Promoting Life-Style Behaviors and Systemic Inflamma-tion in African American and Caucasian Women Prior to Chemo-therapy for Breast Cancer.

Authors:  Debra E Lyon; Lathika Mohanraj; Debra Lynch Kelly; Rk Elswick
Journal:  Health Promot Perspect       Date:  2014-07-12

3.  Breast cancer in the young: role of the geneticist.

Authors:  Ashley H Woodson; Jessica L Profato; Kimberly I Muse; Jennifer K Litton
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

4.  Aberrant low expression of p85α in stromal fibroblasts promotes breast cancer cell metastasis through exosome-mediated paracrine Wnt10b.

Authors:  Y Chen; C Zeng; Y Zhan; H Wang; X Jiang; W Li
Journal:  Oncogene       Date:  2017-04-10       Impact factor: 9.867

5.  Multiplex genetic cancer testing identifies pathogenic mutations in TP53 and CDH1 in a patient with bilateral breast and endometrial adenocarcinoma.

Authors:  Ellen Heitzer; Sigurd Lax; Ingrid Lafer; Stephanie M Müller; Gunda Pristauz; Peter Ulz; Stephan Jahn; Christoph Högenauer; Edgar Petru; Michael R Speicher; Jochen B Geigl
Journal:  BMC Med Genet       Date:  2013-12-29       Impact factor: 2.103

6.  Editorial: BRCA1 and BRCA2 gene mutations screening in sporadic breast cancer patients in Kazakhstan.

Authors:  Rachel C Jankowitz; Kelly Z Knickelbein
Journal:  Cent Asian J Glob Health       Date:  2013-05-21

7.  BRCA1/BRCA2 Mutations Shaped by Ancient Consanguinity Practice in Southern Mediterranean Populations

Authors:  Fadoua Belaiba; Imene Medimegh; Yannick Bidet; Sami Boussetta; Olfa Baroudi; Amel Mezlini; Yves Jean Bignon; Amel Benammar El gaaied
Journal:  Asian Pac J Cancer Prev       Date:  2018-10-26

8.  Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican population.

Authors:  Lenny N Gallardo-Alvarado; María Teresa Tusié-Luna; María Isabel Tussié-Luna; José Díaz-Chávez; Yayoi X Segura; Enrique Bargallo-Rocha; Cynthia Villarreal; Luis A Herrera-Montalvo; Enrique M Herrera-Medina; David F Cantu-de Leon
Journal:  BMC Cancer       Date:  2019-02-01       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.